Table 2b.
Clinical data for NS5B polymerase inhibitors.
| Adverse Events | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | mono | combo | SVR active | SVR SOC | Derm | HA | Const | GI | Psych | Renal | Other |
| ABT-072 | |||||||||||
| ABT-333 | 4.0 | Y | Y | Y | |||||||
| ANA598 | 2.4 | Y | |||||||||
| filibuvir (PF-00868554) | 2.1 | 4.6 | Y | Y | Y | Y | Y | ||||
| GS 9190 | Y | QT | |||||||||
| IDX184 | 0.74 | Y | Y | Y | |||||||
| PSI-7851 (single enantiomer is PSI-7977) | 1.0 | Y | |||||||||
| RG7128 (R7128, RO5024048, prodrug of PSI-6130) | 5.0 | 65% (13/20) | 60% (6/10) | ||||||||
| silibinin (silybin) | Y | ||||||||||
| VCH-222 | 3.7 | ||||||||||
| VCH-759 | 2.5 | Y | Y | Y | |||||||
| VCH-916 | 1.5 | Y | Y | ||||||||
| BI 207127 | 5.6 | Y | |||||||||
| IDX375 | |||||||||||
| MK-3281 | 3.8 | myoclonus | |||||||||
SVR active/SOC: percentage of participants in experimental therapy/SOC group achieving sustained virologic response; Derm: dermatologic adverse events; HA: headache; Const: constitutional (e.g., fever or fatigue); GI: gastrointestinal; Psych: psychiatric; Renal: elevation in kidney function markers; QT: prolongation of the QT interval on electrocardiography, potentially fatal in a subset of patients receiving other QT-prolonging drugs or with the congenital long QT syndrome; Y: adverse event reported in experimental therapy group.